Clinical Trials on Familial Transthyretin Amyloidosis

Total 1612 results

Alnylam Pharmaceuticals

Completed

Trial to Evaluate Safety, Tolerability, and Parmacokinetics of ALN-TTR02 in Healthy Volunteer Subjects

TTR-mediated Amyloidosis

United Kingdom
Jeffrey Zonder

Not yet recruiting

DapagliFLOzin in Renal AL Amyloidosis (FLORAL) (FLORAL)

Renal AL Amyloidosis

United States
Air Force Military Medical University, China

Not yet recruiting

Probiotic Supplementation Reduces Gastrointestinal Symptoms During the Therapy and Improves Therapeutic Response in AL Amyloidosis

Immunoglobulin Light-chain Amyloidosis
PETHEMA Foundation

Completed

Lendexal in Patients With Primary Systemic Amyloidosis (AL) Newly Diagnosed (LENDEXAL)

Primary Systemic Amyloidosis

Spain
National Cancer Institute (NCI)

Terminated

Iododoxorubicin in Treating Patients With Primary Systemic Amyloidosis

Primary Systemic Amyloidosis

United States
Alnylam Pharmaceuticals

Completed

Phase 2 Study to Evaluate ALN-TTRSC (Revusiran) in Patients With Transthyretin (TTR) Cardiac Amyloidosis

TTR-mediated Amyloidosis

United States, United Kingdom
Centre Hospitalier Universitaire de Nīmes

Completed

Cerebellar Superficial Siderosis in Cerebral Amyloid Angiopathy (CSS)

Cerebral Amyloid Angiopathy | Siderosis

France
Groupe Hospitalier Paris Saint Joseph

Completed

The Silent Cortical Infarcts in the Cerebral Amyloid Angiopathy: Is There a Link With Subarachnoid Hemorrhage? (CAA)

CADASIL

France
Federico II University

Enrolling by invitation

Exercise Training and Rehabilitation In Cardiac Amyloidosis (ERICA)

Cardiac Amyloidosis

Italy
Alnylam Pharmaceuticals

Completed

The Study of ALN-TTR02 (Patisiran) for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis in Patients Who Have Already Been Treated With ALN-TTR02 (Patisiran)

TTR-mediated Amyloidosis

Portugal, Sweden, Brazil, United States, France, Spain, Germany
Mayo Clinic

Recruiting

Intracardiac Flow Assessment in Cardiac Amyloidosis

Healthy Adults | Amyloidosis Cardiac

United States
Nelson Leung, MD

Active, not recruiting

Treatment of AA Amyloidosis

AA Amyloidosis

United States
University Hospital, Limoges
Ministry of Health, France

Completed

Intensive Versus Conventional Treatment in Patients With Primary Amyloidosis

Primary Systemic Amyloidosis (AL)

France
GCS Ramsay Santé pour l'Enseignement et la Recherche

Recruiting

Analysis of the Evolution of SUVmax by Quantitative Analysis Method of Bisphosphonate Scintigraphy (QUANTI-SUV)

Cardiac Amyloidosis

France
Wuhan Union Hospital, China

Recruiting

The Diagnostic Value of Hybrid PET/MR for Systemic Amyloidosis

PET/MR | Systemic Amyloidosis

China
Attralus, Inc.

Completed

A Study to Characterize the Biodistribution of 124I-Labeled AT-03 in Patients With Systemic Amyloidosis (AT03-001)

Amyloidosis; Systemic

United States
Jin Lu, MD

Recruiting

Optimize First-line Treatment for AL Amyloidosis With t (11; 14)

AL Amyloidosis | Amyloidosis; Systemic

China
Seoul National University Hospital

Completed

Frontline Lenalidomide for AL Amyloidosis Involving Myocardium

Amyloidosis Cardiac

Korea, Republic of
Boston Medical Center
Spectrum Pharmaceuticals, Inc

Terminated

Propylene Glycol-Free Melphalan Hydrochloride (Evomela) in AL Amyloidosis Patients

Amyloidosis; Systemic

United States
Alnylam Pharmaceuticals

Completed

A Extension Study to Evaluate Revusiran (ALN-TTRSC) in Patients With Transthyretin (TTR) Cardiac Amyloidosis

TTR-mediated Amyloidosis

United States, Canada, United Kingdom
National Taiwan University Hospital

Completed

Application of Amyloid PET in Cerebral Amyloid Angiopathy (CAA)

Alzheimer Disease | Intracranial Hemorrhages | Cerebral Amyloid Angiopathy

Taiwan
Alnylam Pharmaceuticals

Terminated

A Study of the Natural History of Leukocyte Chemotactic Factor 2 Amyloidosis (ALECT2) Disease

Amyloidosis | Leukocyte Chemotactic Factor 2 Amyloidosis

United States, Malaysia, United Kingdom, Mexico, Egypt, India
National Cancer Institute (NCI)

Completed

Melphalan and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Systemic Light-Chain Amyloidosis

Primary Systemic Amyloidosis | Light Chain Deposition Disease

United States
Sorrento Therapeutics, Inc.

Recruiting

Study of the Safety and Efficacy of STI-6129 in Patients With Relapsed or Refractory Systemic AL Amyloidosis

Light Chain (AL) Amyloidosis

United States
Weill Medical College of Cornell University
Janssen Scientific Affairs, LLC

Recruiting

Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Relapsed/Refractory Light Chain Amyloidosis Patients Previously Exposed to Daratumumab

AL Amyloidosis | Amyloid | Refractory AL Amyloidosis

United States
IRCCS Policlinico S. Matteo

Terminated

A Trial of Doxycycline vs. Standard Supportive Therapy in Newly-diagnosed Cardiac AL Amyloidosis Patients Undergoing Bortezomib-based Therapy

Cardiac AL Amyloidosis

Spain, France, Italy, Germany, Canada, Greece, Turkey, United Kingdom
Mayo Clinic

Completed

Bortezomib, Cyclophosphamide, and Dexamethasone in Treating Patients With Primary Systemic Light Chain Amyloidosis

Primary Systemic Amyloidosis

United States
The Cleveland Clinic

Completed

Phase II Trial of Enbrel in Patients With Primary Systemic Amyloidosis

Primary Systemic Amyloidosis
Sorrento Therapeutics, Inc.

Withdrawn

An Open-Label Study of the Safety of an Anti-CD38 Antibody Drug Conjugate (STI-6129) in Patients With AL Amyloidosis

Light Chain (AL) Amyloidosis
Medical College of Wisconsin
National Heart, Lung, and Blood Institute (NHLBI)

Completed

Doxycycline to Upgrade Organ Response in Light Chain (AL) Amyloidosis Trial (DUAL)

Primary Systemic Amyloidosis

United States
National Taiwan University Hospital

Recruiting

Multimodal Biomarkers for Diagnosis and Prognosis in CAA (CAA)

Alzheimer Disease | Intracranial Hemorrhages | Cerebral Amyloid Angiopathy

Taiwan
Boston Medical Center
Millennium Pharmaceuticals, Inc.

Completed

Bortezomib and Dexamethasone Followed by High-Dose Melphalan and Stem Cell Transplantation for Primary (AL) Amyloidosis

Amyloidosis

United States
Istanbul University

Completed

Recurrent AA Amyloidosis After Renal Transplantation

AA Amyloidosis

Turkey
Assistance Publique - Hôpitaux de Paris

Not yet recruiting

Unclassified GENotypes of Autoinflammatory Diseases and AA Amyloidosis (IPHYGENI MAI)

Autoinflammatory Disease | AA Amyloidosis
University of Leipzig

Recruiting

Cardiac Amyloidosis Registry of University Hospital Leipzig

Cardiac Amyloidosis

Germany
Wake Forest University Health Sciences

Recruiting

CAPACITY (Cardiac Amyloidosis and Physical ACtivITY) Study (CAPACITY)

Cardiac Amyloidosis

United States
Brigham and Women's Hospital

Recruiting

Molecular Imaging of Myocardial Fibrosis in Cardiac Amyloidosis

Cardiac Amyloidosis

United States
European Myeloma Network
Janssen Pharmaceutica

Active, not recruiting

A Study of Daratumumab Monotherapy in Previously Untreated Patients With Stage 3B Light Chain (AL) Amyloidosis

Light Chain (AL) Amyloidosis, Stage 3B

Netherlands, Greece, France, Italy
Guangdong Provincial People's Hospital

Recruiting

Comparison of BTD and BCD Based Regimens in the Treatment of AL Amyloidosis

Immunoglobulin Light-Chain Amyloidosis

China
IRCCS Policlinico S. Matteo

Terminated

Epigallocatechingallate (EGCG) in Cardiac AL Amyloidosis (EpiCardiAL)

Primary Amyloidosis of Light Chain Type

Italy
IRCCS Policlinico S. Matteo

Completed

Pomalidomide and Dexamethasone (PDex) in AL Amyloidosis

Primary Amyloidosis of Light Chain Type

Italy
AstraZeneca

Recruiting

OverTTuRe: Characteristics, Treatment Patterns and Outcomes of Patients With ATTR Amyloidosis (OverTTuRe)

ATTR Amyloidosis

United Kingdom, United States, Denmark, Japan
Selayang Hospital

Completed

A Randomised, Open-Label, Cross Over Group, Single-Centre Controlled Study To Evaluate The Clinical Performance Of Medium Cut-Off Membrane Dialyser Compared With High Flux Dialyser Among Patients With Chronic Haemodialysis (HD-1)

Quality of Life | Dialysis Amyloidosis | Hemodialysis-Associated Amyloidosis

Malaysia
Barbara Ann Karmanos Cancer Institute
Bristol-Myers Squibb; National Cancer Institute (NCI); Multiple Myeloma Research...

Active, not recruiting

Lenalidomide, Dexamethasone, and Elotuzumab With or Without Cyclophosphamide in Treating Patients With Relapsed Primary Amyloidosis

Recurrent Primary Amyloidosis

United States
Brigham and Women's Hospital

Completed

Doxycycline and TUDCA in Patients With Transthyretin Amyloid Cardiomyopathy

Amyloidosis; Heart (Manifestation) | Senile Cardiac Amyloidosis

United States
Leiden University Medical Center

Recruiting

Coach Pilot Study: Assessing Cognitive Function and Related Small Vessel Disease Markers After Intracerebral Hemorrhage (COACH)

Cognitive Decline | Cerebral Amyloid Angiopathy | Intracerebral Hemorrhage | Hypertensive Hemorrhage, Intracranial

Netherlands
Heinrich-Heine University, Duesseldorf

Not yet recruiting

Virtual Reality Assisted Patient Empowerment: Diagnose ATTR-Amyloidosis And Start Treatment (VRAP-DAAST)

Virtual Reality | Amyloidosis Cardiac

Germany
Far Eastern Memorial Hospital

Not yet recruiting

A Multi-center Cardiac PYP Scan Registry in Taiwan.

Heart Failure | Cardiac Amyloidosis

Taiwan
University of Pennsylvania
Fox Chase Cancer Center

Completed

Penn Biobank Return of Research Results Program

Cardiovascular Diseases | Cancer | Hereditary Cancer | Hereditary Cardiac Amyloidosis

United States
Regeneron Pharmaceuticals

Not yet recruiting

A Trial to Learn if Linvoseltamab is Safe and Works in Adults With Relapsed or Refractory Systemic Light Chain Amyloidosis (AL Amyloidosis) (LINKER-AL2)

Relapsed/Refractory Systemic Light Chain Amyloidosis

Clinical Trials on Familial Transthyretin Amyloidosis

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Moldova

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations